Twist Bioscience Stock Jumps After Launch of Fast Antibody Screening Service
Twist Bioscience shares climbed about 10% after the company launched an antibody testing service for AI drug discovery, with turnaround as short as five days.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Shares of Twist Bioscience rose after the biotech company announced a service able to produce and rapidly assess antibodies for research into AI-based drug discovery, Dow Jones Newswires reported. Around midday Wednesday the stock traded up 10% at $175.81, and it has more than quintupled so far this year.
The company says the offering, with a turnaround of as little as five days, aims to narrow the gap between early antibody binding data and later drug development. Chief Executive Officer Emily Leproust said: "Twist Express Screening Antibodies bring speed and scalability to early-stage characterization, enabling researchers to move broader candidate sets from sequence to data, iterate faster and focus downstream development resources on the antibodies with the greatest potential."
why it matters
The move mainly reflects one company, yet it shows investors rewarding firms that link lab services to AI-driven drug development.
market impact
Twist Bioscience shares: a new AI-focused service supports the stock after a sharp rally this year.
- Twist Bioscience shares pressure up — new AI-focused antibody service adds to investor interest
tags
instruments
sources
- Twist Bioscience Shares Gain on Antibody Evaluating Service — Dow Jones Newswires, 28 October 2026 at 16:03 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗